Pulmonx to Report Third Quarter 2024 Financial Results on October 30, 2024

REDWOOD CITY, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) — Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the third quarter of 2024 after the close of trading on Wednesday, October 30, 2024. Company management will host a conference call […]

PDF Solutions to Report Third Quarter Fiscal 2024 Financial Results on November 7, 2024

SANTA CLARA, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) — PDF Solutions, Inc. (Nasdaq: PDFS), a leading provider of comprehensive data solutions for the semiconductor ecosystem, announced that it will release Third quarter fiscal 2024 financial results after the market close on Thursday, November 7, 2024. John Kibarian, CEO, and Adnan Raza, CFO, will host a

iRhythm Technologies to Report Third Quarter 2024 Financial Results on October 30, 2024

SAN FRANCISCO, Oct. 16, 2024 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the third quarter 2024 after the close of trading on Wednesday, October 30, 2024. The company’s management

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

In vitro data on SPR719 show low propensity for resistance development in NTM-PD MAC strains when administered as a single agent and in combination with standard of care agents Study highlighting SPR720 potential benefits for prolonged combination regimens typical to NTM-PD treatment CAMBRIDGE, Mass., Oct. 16, 2024 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO),

Stifel Financial Schedules Third Quarter 2024 Financial Results Conference Call

ST. LOUIS, Oct. 16, 2024 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) will release its third quarter 2024 financial results before the market opens on Wednesday, October 23, 2024. The company will host a conference call to review the results at 9:30 a.m. Eastern time that same day. The conference call may include forward-looking

TEDCO Releases Equitech Growth Commission’s Preliminary Funding Plan and Priorities

Announces Inaugural Request for Applications through the Equitech Growth Fund with up to $5M in Estimated Awards TEDCO, Maryland’s economic engine for technology companies, announces the release of the Equitech Growth Commission’s Preliminary Funding Plan and Priorities, along with a Request for Applications (RFA) for the inaugural round of Equitech funding. The Commission’s preliminary plan,

Global Perspectives on the Circular Economy: Paving the Way for a Sustainable Future

“Stakeholders and Governments Transition from Linear to Circular Economy, Embracing Recycling, Refurbishing, and Reusing for Sustainable Resource Management” “The latest BCC Research study on “Circular Economy: A Global Outlook” presents a thorough global circular economy market analysis, emphasizing its current state and future prospects. The report delves into key market drivers, limitations, challenges, and opportunities,

Direct Digital Holdings Regains Nasdaq Compliance

Direct Digital Holdings, Inc. (Nasdaq: DRCT) (“Direct Digital Holdings” or the “Company”), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (“Colossus SSP”), Orange 142, LLC (“Orange 142”) and Huddled Masses LLC (“Huddled Masses”), announced today that it received written notice from the staff of the Listing Qualifications Department (the

CSX Corp. Announces Third Quarter 2024 Results

JACKSONVILLE, Fla., Oct. 16, 2024 (GLOBE NEWSWIRE) — CSX Corp. (NASDAQ: CSX) today announced third quarter 2024 operating income of $1.35 billion compared to $1.27 billion in the prior year period. Net earnings were $894 million, or $0.46 per diluted share, compared to $828 million, or $0.41 per diluted share, in the same period last

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

KELOWNA, BC / ACCESSWIRE / October 16, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX; LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, today announced that it has closed its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 1,633,987 shares of common stock at a

Scroll to Top